Here are five takeaways:
1. The subcommittee members concluded Medicare has fallen short of its duty to promote prevention and treatment of opioid abuse. Little data exists concerning Medicare members’ opioid use and providers’ prescribing patterns to this population.
2. Effective in 2019, CMS proposes Part D plans restrict pharmacies from delivering prescriptions “more than a 90 morphine milligram equivalent, or a seven-day supply,” Medscape reports.
3. Additionally, CMS called for Medicare Part D prescription drug plans to pay close attention to patients using gabapentin and pregabalin, labeled as “potentiator” drugs leading to opioid misuse.
4. The proposal also includes a quality measure to track Part D plans’ ability to “flag concurrent use of opioids and benzodiazepines,” according to Medscape.
5. CMS will accept comments until March 5, publishing final requirements April 2.
More articles on practice management:
Missouri Care appoints Dr. Ronald Lopez senior medical director — 5 highlights
PEAK Sport and Spine buys laser spine center in Missouri: 4 notes
Arthrex honors Dr. Peter Millett for research on improving patient outcomes: 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
